Organon & Co. (NYSE:OGN) Shares Acquired by Royce & Associates LP

Royce & Associates LP lifted its position in shares of Organon & Co. (NYSE:OGN - Free Report) by 23.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 869,394 shares of the company's stock after buying an additional 166,300 shares during the period. Royce & Associates LP owned 0.34% of Organon & Co. worth $12,971,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC raised its holdings in Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after acquiring an additional 84,136 shares during the last quarter. Weiss Asset Management LP purchased a new stake in shares of Organon & Co. in the third quarter valued at $32,966,000. Cerity Partners LLC grew its position in shares of Organon & Co. by 94.0% in the third quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock valued at $12,766,000 after purchasing an additional 323,308 shares during the period. Foundry Partners LLC acquired a new position in Organon & Co. in the third quarter valued at $7,642,000. Finally, Robeco Institutional Asset Management B.V. purchased a new position in Organon & Co. during the fourth quarter worth about $2,263,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on OGN. Barclays lowered their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Organon & Co. currently has an average rating of "Hold" and an average target price of $20.80.

Remove Ads

Organon & Co. Trading Down 1.7 %

Shares of NYSE:OGN traded down $0.27 during trading on Friday, reaching $15.33. 20,287,898 shares of the stock were exchanged, compared to its average volume of 2,412,218. The firm's 50-day moving average price is $15.45 and its 200 day moving average price is $16.54. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of 4.60, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. On average, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.31%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.